Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
Delia Bishara1, David Taylor1,21Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK; 2Division of Pharmaceutical Sciences, King’s College, London, UKAbstract: Asenapine is a new atypical antipsychotic agent currently under development for the t...
Saved in:
Main Authors: | Delia Bishara, David Taylor |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2009
|
Subjects: | |
Online Access: | https://doaj.org/article/a505025bb6854ca5b5e8c41bb5f7597a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Asenapine for bipolar disorder
by: Scheidemantel T, et al.
Published: (2015) -
Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
by: Gao K, et al.
Published: (2013) -
The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder
by: Pompili M, et al.
Published: (2011) -
New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania
by: Warren CG, et al.
Published: (2013) -
Role of sublingual asenapine in treatment of schizophrenia
by: Citrome L
Published: (2011)